Feasibility of re-biopsy and EGFR mutation analysis in patients with non-small cell lung cancer
Published 2018 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Feasibility of re-biopsy and EGFR
mutation analysis in patients with non-small cell lung cancer
Authors
Keywords
-
Journal
Thoracic Cancer
Volume 9, Issue 7, Pages 856-864
Publisher
Wiley
Online
2018-05-15
DOI
10.1111/1759-7714.12762
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Molecular Adequacy of Image-Guided Rebiopsies for Molecular Retesting in Advanced Non–Small Cell Lung Cancer: A Single-Center Experience
- (2018) Nadza Tokaca et al. Journal of Thoracic Oncology
- Peptide Nucleic Acid Clamping and Direct Sequencing in the Detection of Oncogenic Alterations in Lung Cancer: Systematic Review and Meta-Analysis
- (2018) Jae-Uk Song et al. YONSEI MEDICAL JOURNAL
- A Higher Proportion of the EGFR T790M Mutation May Contribute to the Better Survival of Patients with Exon 19 Deletions Compared with Those with L858R
- (2017) E-E Ke et al. Journal of Thoracic Oncology
- Application of Plasma Genotyping Technologies in Non–Small Cell Lung Cancer: A Practical Review
- (2017) Adrian G. Sacher et al. Journal of Thoracic Oncology
- Molecular profiling in Italian patients with advanced non-small-cell lung cancer: An observational prospective study
- (2017) Elisa Gobbini et al. LUNG CANCER
- Frequency of EGFR T790M mutation and multimutational profiles of rebiopsy samples from non-small cell lung cancer developing acquired resistance to EGFR tyrosine kinase inhibitors in Japanese patients
- (2016) Ryo Ko et al. BMC CANCER
- Rebiopsy for patients with non-small-cell lung cancer after epidermal growth factor receptor-tyrosine kinase inhibitor failure
- (2016) Takahisa Kawamura et al. CANCER SCIENCE
- Association Between Plasma Genotyping and Outcomes of Treatment With Osimertinib (AZD9291) in Advanced Non–Small-Cell Lung Cancer
- (2016) Geoffrey R. Oxnard et al. JOURNAL OF CLINICAL ONCOLOGY
- Re-biopsy status among non-small cell lung cancer patients in Japan: A retrospective study
- (2016) Kaname Nosaki et al. LUNG CANCER
- The emergence of T790M mutation in EGFR-mutant lung adenocarcinoma patients having a history of acquired resistance to EGFR-TKI: focus on rebiopsy timing and long-term existence of T790M
- (2016) Jeng-Sen Tseng et al. Oncotarget
- Association of EGFR Exon 19 Deletion and EGFR-TKI Treatment Duration with Frequency of T790M Mutation in EGFR-Mutant Lung Cancer Patients
- (2016) Norikazu Matsuo et al. Scientific Reports
- Feasibility of Rebiopsy in Non-Small Cell Lung Cancer Treated with Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors
- (2015) Takaaki Hasegawa et al. INTERNAL MEDICINE
- EGFR mutation detection in ctDNA from NSCLC patient plasma: A cross-platform comparison of leading technologies to support the clinical development of AZD9291
- (2015) Kenneth S. Thress et al. LUNG CANCER
- AZD9291 in EGFR Inhibitor–Resistant Non–Small-Cell Lung Cancer
- (2015) Pasi A. Jänne et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer
- (2015) Edward B. Garon et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer
- (2015) Julie Brahmer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer
- (2015) Hossein Borghaei et al. NEW ENGLAND JOURNAL OF MEDICINE
- Peptide Nucleic Acid Clamping Versus Direct Sequencing for the Detection of EGFR Gene Mutation in Patients with Non-small Cell Lung Cancer
- (2015) Seong-Hoon Yoon et al. Cancer Research and Treatment
- Feasibility and clinical impact of re-biopsy in advanced non small-cell lung cancer: A prospective multicenter study in a real-world setting (GFPC study 12-01)
- (2014) Christos Chouaid et al. LUNG CANCER
- Incidence of T790M mutation in (sequential) rebiopsies in EGFR-mutated NSCLC-patients
- (2014) J.L. Kuiper et al. LUNG CANCER
- Impact of EGFR Mutation Detection Methods on the Efficacy of Erlotinib in Patients with Advanced EGFR-Wild Type Lung Adenocarcinoma
- (2014) Jeng-Sen Tseng et al. PLoS One
- Rebiopsy of non-small cell lung cancer patients with acquired resistance to epidermal growth factor receptor-tyrosine kinase inhibitor
- (2013) Akito Hata et al. CANCER
- Analysis of Tumor Specimens at the Time of Acquired Resistance to EGFR-TKI Therapy in 155 Patients with EGFR-Mutant Lung Cancers
- (2013) H. A. Yu et al. CLINICAL CANCER RESEARCH
- Clinical implications of T790M mutation in patients with acquired resistance to EGFR tyrosine kinase inhibitors
- (2013) Jong-Mu Sun et al. LUNG CANCER
- Rebiopsy of Lung Cancer Patients with Acquired Resistance to EGFR Inhibitors and Enhanced Detection of the T790M Mutation Using a Locked Nucleic Acid-Based Assay
- (2011) M. E. Arcila et al. CLINICAL CANCER RESEARCH
- Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study
- (2011) Caicun Zhou et al. LANCET ONCOLOGY
- Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors
- (2011) L. V. Sequist et al. Science Translational Medicine
- Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR
- (2010) Makoto Maemondo et al. NEW ENGLAND JOURNAL OF MEDICINE
- Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial
- (2008) Edward S Kim et al. LANCET
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search